Procter & Gamble Company (The) (PG) Stock Price & How to Invest

Procter & Gamble is one of the world's largest consumer-products companies, selling everyday household and personal-care brands used by billions of people. Its portfolio is organized into segments spanning fabric and home care (Tide, Ariel, Downy, Dawn, Febreze), baby, feminine, and family care (Pampers, Always, Bounty, Charmin), beauty (Olay, Pantene, Head & Shoulders, SK-II), grooming (Gillette, Venus), and health care (Crest, Oral-B, Vicks, Metamucil). P&G makes money selling these branded products through retailers, e-commerce, and other channels worldwide, relying on scale, marketing, and continual product innovation to command premium pricing and shelf space. The company deliberately pruned its portfolio over the past decade to focus on a smaller set of large, profitable, daily-use categories. Founded in 1837 and headquartered in Cincinnati, Ohio, P&G is a classic defensive blue chip and a Dividend King, prized for steady cash flow, pricing power, and an exceptionally long record of dividend increases.

In fiscal 2026 (the year ended June 30, 2026) P&G generated about $87 billion of revenue, up from about $84.3 billion, and about $16 billion of net earnings, with free cash flow of roughly $13.3 billion. Growth slowed through the year: quarterly revenue eased from about $22.4 billion in the September 2025 quarter to about $21.2 billion in the June 2026 quarter, and fourth-quarter EPS of $1.43 edged past the $1.41 consensus. The stock has held up anyway, rising about 12% in 2026 to a forward P/E near 21.5.

P&G's mature categories grow slowly, so organic growth depends on modest pricing and volume gains; in a low-inflation environment, raising prices further is harder and volumes can soften if shoppers trade down to private-label alternatives. That slowdown is now visible: revenue grew only about 1.5% year over year in the latest quarter, and analysts expect fiscal 2027 revenue of about $88.9 billion and EPS of about $6.98, roughly 1% growth, with the September-quarter consensus of $1.89 down about 5% from a year earlier. A large share of sales comes from outside the US, exposing earnings to a strong dollar and emerging-market currency swings. Input-cost inflation (commodities, energy, transportation) can pressure margins. Private-label competition and shifting retailer dynamics, including the bargaining power of large retailers, are persistent threats. The defensive profile also means the stock can lag sharply in strong bull markets, and its premium valuation (about 24 times trailing earnings) leaves little room for execution missteps.

23 analysts publish price targets on PG, averaging $161.65 against a $159.35 price as of October 2026, or +1.4%. The published targets run from $143.00 to $186.00, a narrow spread, and the ratings split 13 buy, 12 hold, 0 sell. Over the last six months there have been 3 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PG forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Procter & Gamble Company (The). Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Brand strength and pricing power. P&G owns category-leading brands in daily-use staples, which gives it durable pricing power. The most optimistic published target, $186.00, assumes this works close to its best case.

The case against. P&G's mature categories grow slowly, so organic growth depends on modest pricing and volume gains; in a low-inflation environment, raising prices further is harder and volumes can soften if shoppers trade down to private-label alternatives. The most pessimistic target, $143.00, is roughly what PG is worth if this bites instead.

Read the full bull and bear case on PG, including what would have to change to break either one. Walnut is not an investment adviser.

No. Procter & Gamble Company (The) (PG) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Procter & Gamble Company (The)'s investor relations page or your broker.

• Revenue (fiscal 2026): ~$87 billion, +1.5% yoy in the June quarter
• Operating margin: ~22%
• Net margin: ~18% (~$16 billion net income)
• Free cash flow: ~$13.3 billion (TTM)
• EPS (trailing / forward): ~$6.62 / ~$7.39
• P/E (trailing / forward): ~24x / ~21.5x
• Dividend yield: ~2.8% ($4.35/yr), 70-year increase streak
• Market cap: ~$370 billion

P&G is a high-margin, cash-rich consumer-staples leader that commands a premium valuation for its brand strength, defensiveness, and unmatched dividend record. At $159.10 in mid-October 2026 it trades around 24 times trailing and 21.5 times forward earnings while consensus calls for roughly flat EPS in fiscal 2027, so the price leans on stability and capital return rather than growth. The fiscal Q1 2027 report on October 22 (consensus EPS about $1.89 on $22.8 billion of revenue) is the next test.

If you want PG exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses PG naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to PG: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get PG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (HDV, DGRO, SCHD), which spreads the position across many companies. Or build it into a focused thematic portfolio, so PG sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Procter & Gamble (PG) turns recession-resistant demand for detergent, diapers, and toothpaste into reliable, growing capital return, so its appeal is stability and pricing power rather than rapid growth. In a portfolio it behaves as a low-volatility, defensive consumer-staples and dividend anchor that tends to lag in strong bull markets and hold up in downturns, a pattern visible again in late 2026 as the shares rose about 9% in a month while investors leaned defensive ahead of fiscal first-quarter results on October 22.

Whether PG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PG a buy or a sell?, and where the stock could go from here in the PG stock forecast.

For income investors, whether PG pays a dividend and how the payout looks is covered in does PG pay a dividend? And to weigh PG against a peer, read the full side-by-side comparisons: PG vs COST and PG vs JNJ.